ERBB2 and breast carcinoma: SFRP1 was correlated to pathological complete response and relapse-free survival status at 5 years in breast cancer regardless of any chemotherapy, hormone therapy, and anti-HER2 therapy, therefore, SFRP1 could act as a predictive biomarker to predict response among patients with breast cancer.